Following U.S. Stocks may claim a “BIG Change,” in the course of current trading session: Great Basin Scientific Inc (NASDAQ:GBSN), Synta Pharmaceuticals Corp (NASDAQ:SNTA)
Great Basin Scientific Inc (NASDAQ:GBSN), with shares Skyrocketed 63.11% is now trading at $3.89. The Stock is active as 3.20M shares changed hands versus its average volume of 178,463.00 shares.
Synta Pharmaceuticals Corp (NASDAQ:SNTA), with shares dwindled -17.60% is now trading at $1.92. The Stock is active as 6.64M shares changed hands versus its average volume of 901,061.00 shares.
Latest NEWS regarding these Stocks are depicted underneath:
Great Basin Scientific, Inc. (NASDAQ:GBSN)
Today, Great Basin Scientific, Inc. (GBSN), declared that the United States Patent and Trademark Office (USPTO) issued a notice of allowance for patent 8,936,921 for the Corporation’s method of isothermal helicase-dependent amplification (HDA) using blocked primers (bp), or “bpHDA.” bpHDA creates a highly specific “hot-start” functionality which raises the amplification speed, improves assay sensitivity and expands multiplex capabilities of Great Basin’s sample-to-result molecular diagnostic testing technology. bpHDA is the basis of the Corporation’s Clostridium difficile (C. diff) molecular diagnostic test assay.
This newly issued patent further enhances the Corporation’s patent family, which comprises U.S. patent 8,637,250 (issued Jan. 28, 2014) for systems and methods for point-of-care amplification and detection of polynucleotides covering isothermal amplification using HDA on the surface of chips. This patent permits future simplification of Great Basin’s chip technology which would further lower costs, raise speed, and potentially allow for a field-deployable approach for molecular diagnostics. U.S. patent 8,574,833 (issued on Nov. 5, 2013) covers methods and compositions for amplifying a detectable signal. The method, termed AMPED, is a cost-effective approach for direct detection of pathogens present in clinical samples such as blood, lung aspirates, urine, stool and swabs at low levels without the requirement of PCR-based target amplification. Great Basin asserts that by eliminating the amplification step used in other methods, their technology has the potential to provide faster results at a lower cost.
Great Basin Scientific is a molecular diagnostics corporation that commercializes breakthrough chip-based technologies. The Corporation is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Today, Synta Pharmaceuticals Corp. (SNTA), declared that it has priced an underwritten public offering of 22,000,000 shares of its ordinary stock at a price to the public of $1.75 per share. Gross proceeds to Synta are predictable to be about $38.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The offering is predictable to close on or about April 6, 2015, subject to satisfaction of customary closing conditions. Synta has granted the underwriters a thirty (30) day option to purchase up to 3,300,000 additional shares.
Jefferies LLC and Cowen and Corporation, LLC are acting as joint book-running managers for the offering, and JMP Securities LLC and Roth Capital Partners, LLC are acting as co-managers for the offering.
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical corporation focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
